Perspectives
Analytics show super spenders account for nearly 10% of total drug spend
Studies on members with drug costs over $250,000 yield predictive modeling data
February 21, 2021Ongoing studies using integrated benefits data on drug super spenders – members with total drug costs over $250,000 a year – provide predictive modeling data that can help manage outcomes and control costs
Ongoing studies using integrated benefits data on drug super spenders – members with total drug costs over $250,000 a year – provide predictive modeling data that can help manage outcomes and control costs
For many specialty conditions, nearly 90% of the total cost of care can come from drugs. That’s why Prime’s expertise at drug management is so important in controlling costs.
This study categorized and described trends in the medical conditions accounting for these member’s extraordinary drug expense.
This study contributes to Prime’s understanding of which drugs, conditions, and other factors can result in drug super spenders. It contributes to Prime’s ability to identify such members early by predictive modeling, and strategies to improve management of high cost specialty drugs. Integrated pharmacy claims analysis helps to confirm effectiveness of clinical programs and to identify additional opportunities.
Related news
Perspectives
June 1, 2023
Prime reimagines patient care, unites care team for a better experience and smarter treatment plan
The patient journey from a cancer diagnosis through treatment with multiple specialty medications…
Perspectives
May 30, 2023
Specialty Drug Pipeline Update: May 2023
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…
Perspectives
May 30, 2023
Traditional Drug Pipeline Update: May 2023
This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…